Novartis, Antisoma Taking on Avastin in Lung Cancer Market



Novartis, Antisoma Taking on Avastin in Lung Cancer Market

November 20, 2007--Novartis and its partner, Antisoma, announced revised clinical trial plans for their experimental drug ASA404; the new study program pits ASA404 against Roche and Genentech’s blockbuster drug Avastin. Novartis, which licensed rights to ASA404 from Antisoma in April, had originally planned to test the drug only in patients with squamous non-small cell lung cancer, who cannot use Avastin. The new Phase III program will include non-squamous patients too. Reuters 

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

IBM
DESKTOP ENGINEERING WITH IBM:
High Performance Cluster Computing Survey
Sponsored by IBM Platform Computing


Tessella logo
Target Analytics Maturity to Beat the Big Data Backlash
Sponsored by Tessella


New Medidata logo
Why Monitoring Is More Than Just SDV
Sponsored by Medidata


Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now  

More Podcasts

Job Openings

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.